Meng Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meng Su has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Changlin Zou
Department of Radiotherapy and Chemotherapy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
5 shared publications Yang Zhang
3 shared publicationsCan Wang
2 shared publicationsKe-Jie Li
Department of Radiotherapy, the First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China
2 shared publications- Da-Hai Zhang
Department of Oncological Radiotherapy, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, People’s Republic of China
1 shared publication - Dexi Du
Department of Radiation Oncology, Lishui Central Hospital, Lishui, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Forum Multimedia Publishing LLC in European Cells and Materials
- Vol. 56, 48-63
MECHANISTIC ROLE OF THBS1-LOADED HEK293-DERIVED EXOSOMES IN SUPPRESSING ENDOMETRIAL CANCER: INVOLVEMENT OF TGF-Β SIGNALING AND EXTRACELLULAR MATRIX DYNAMICS
Background: Endometrial cancer (EC) is a prevalent gynecological malignancy with limited therapeutic options due to drug resistance and systemic toxicity. Exosomes have emerged as promising targeted drug delivery vehicles, but their application in EC remains underexplored. Thrombospondin-1 (THBS1), a key regulator of extracellular matrix remodeling and transforming growth factor β (TGF-β) signaling, may offer a novel therapeutic strategy for EC. Methods: Differentially expressed genes were identified from the public transcriptomic datasets and subjected to GO and KEGG enrichment analyses. Exosomes derived from Human embryonic kidney 293 (HEK293) cells overexpressing THBS1 were isolated and characterized by Western blotting, transmission electron microscopy, and nanoparticle tracking analysis. Their effects on EC cells were assessed using Cell Counting Kit-8, 5-ethynyl-2’-deoxyuridine incorporation, colony formation, wound healing, and cell invasion assays. TGF-β pathway involvement was assessed using the agonist SRI-011381. In vivo experiments were conducted to evaluate tumor growth, epithelial–mesenchymal transition (EMT) marker expression, and treatment safety. Results: THBS1 expression was downregulated in the EC cells. The restoration of THBS1 expression through exosome delivery inhibited cell proliferation, migration, and invasion. THBS1-overexpressing exosomes attenuated the activation of the TGF-β/Smad pathway and modulated EMT-related markers. The inhibitory effects of THBS1-exosomes were reversed by SRI-011381. In vivo, THBS1-exosome treatment markedly suppressed tumor growth, enhanced E-cadherin expression, reduced vimentin levels, and exhibited no observable toxicity. Conclusions: Exosomes overexpressing THBS1 effectively suppressed EC progression by targeting the TGF-β/Smad signaling axis and EMT. These findings support the potential of THBS1-enriched exosomes as a novel, safe, and targeted therapeutic modality for future EC.
- 30 April 2026
- Published by Forum Multimedia Publishing LLC in European Cells and Materials
- Vol. 56, 48-63
Open AccessMECHANISTIC ROLE OF THBS1-LOADED HEK293-DERIVED EXOSOMES IN SUPPRESSING ENDOMETRIAL CANCER: INVOLVEMENT OF TGF-Β SIGNALING AND EXTRACELLULAR MATRIX DYNAMICS
Background: Endometrial cancer (EC) is a prevalent gynecological malignancy with limited therapeutic options due to drug resistance and systemic toxicity. Exosomes have emerged as promising targeted drug delivery vehicles, but their application in EC remains underexplored. Thrombospondin-1 (THBS1), a key regulator of extracellular matrix remodeling and transforming growth factor β (TGF-β) signaling, may offer a novel therapeutic strategy for EC. Methods: Differentially expressed genes were identified from the public transcriptomic datasets and subjected to GO and KEGG enrichment analyses. Exosomes derived from Human embryonic kidney 293 (HEK293) cells overexpressing THBS1 were isolated and characterized by Western blotting, transmission electron microscopy, and nanoparticle tracking analysis. Their effects on EC cells were assessed using Cell Counting Kit-8, 5-ethynyl-2’-deoxyuridine incorporation, colony formation, wound healing, and cell invasion assays. TGF-β pathway involvement was assessed using the agonist SRI-011381. In vivo experiments were conducted to evaluate tumor growth, epithelial–mesenchymal transition (EMT) marker expression, and treatment safety. Results: THBS1 expression was downregulated in the EC cells. The restoration of THBS1 expression through exosome delivery inhibited cell proliferation, migration, and invasion. THBS1-overexpressing exosomes attenuated the activation of the TGF-β/Smad pathway and modulated EMT-related markers. The inhibitory effects of THBS1-exosomes were reversed by SRI-011381. In vivo, THBS1-exosome treatment markedly suppressed tumor growth, enhanced E-cadherin expression, reduced vimentin levels, and exhibited no observable toxicity. Conclusions: Exosomes overexpressing THBS1 effectively suppressed EC progression by targeting the TGF-β/Smad signaling axis and EMT. These findings support the potential of THBS1-enriched exosomes as a novel, safe, and targeted therapeutic modality for future EC.
- Open Access
- 22 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1503262
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.
- 22 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1503262
Open AccessBrigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.
- Open Access
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1297156
Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
Lung cancer is the leading cause of cancer death, accounting for one-third of all cancer deaths worldwide. The MET (c-MET) gene, as one of the therapeutic target spots of NSCLC, has become increasingly more important. MET amplification/overexpression was divided into primary (intrinsic) and secondary (acquired). Studies indicated that the combination of Osimertinib and Savolitinib was safe and showed promising antitumor effect in NSCLC patients with secondary MET amplification after EGFR mutations. However, NSCLC patients with primary MET amplification/overexpression and EGFR mutations are rare in clinics, and the efficacy of dual-target therapy combined with EGFR-TKI and Savolitinib for them has not been studied yet. Here, we reported two NSCLC patients with primary MET amplification/overexpression and EGFR mutation, who benefited from T+S therapy (the dual-target therapy of EGFR-TKI plus Savolitinib) and achieved a progression-free survival (PFS) of approximately 5 months. The two cases indicated that T+S therapy has an acceptable safety profile and encouraging antitumor efficacy in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation. Meanwhile, the observation stresses the importance of genetic testing, and the MET gene needs to be detected at first diagnosis for the best choice of targeted therapies.
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1297156
Open AccessCase report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
Lung cancer is the leading cause of cancer death, accounting for one-third of all cancer deaths worldwide. The MET (c-MET) gene, as one of the therapeutic target spots of NSCLC, has become increasingly more important. MET amplification/overexpression was divided into primary (intrinsic) and secondary (acquired). Studies indicated that the combination of Osimertinib and Savolitinib was safe and showed promising antitumor effect in NSCLC patients with secondary MET amplification after EGFR mutations. However, NSCLC patients with primary MET amplification/overexpression and EGFR mutations are rare in clinics, and the efficacy of dual-target therapy combined with EGFR-TKI and Savolitinib for them has not been studied yet. Here, we reported two NSCLC patients with primary MET amplification/overexpression and EGFR mutation, who benefited from T+S therapy (the dual-target therapy of EGFR-TKI plus Savolitinib) and achieved a progression-free survival (PFS) of approximately 5 months. The two cases indicated that T+S therapy has an acceptable safety profile and encouraging antitumor efficacy in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation. Meanwhile, the observation stresses the importance of genetic testing, and the MET gene needs to be detected at first diagnosis for the best choice of targeted therapies.
- Open Access
- 25 May 2023
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 41 (11) , 1275-1289
Curcumol β-cyclodextrin inclusion complex enhances radiosensitivity of esophageal cancer under hypoxic and normoxic condition
Purpose: Radiotherapy is an indispensable treatment for esophageal cancer (EC), but radioresistance is not uncommon. Curcumol, as an active extract from traditional Chinese medicines, has been reported to have antitumor activity in various types of human tumor cells. However, its reversal of radioresistance has been rarely reported. Materials and methods: In the present study, curcumol was prepared as an inclusion complex with β-cyclodextrin. EC cell lines were treated with radiation and curcumol β-cyclodextrin inclusion complex (CβC), and the effect of radiosensitization of CβC was investigated in vitro and in vivo. The in vitro experiments included cell proliferation assay, clonogenic survival assay, apoptosis assay, cell cycle assay, and western blot assay. Results: The in vitro data revealed that CβC and irradiation synergistically inhibited the proliferation, reduced the colony formation, promoted the apoptosis, increased the G2/M phase, inhibited DNA damage repair, and reversed the hypoxia-mediated radioresistance of EC cells to a greater extent than did CβC alone or irradiation alone. The sensitization enhancement ratios (SERs) were 1.39 for TE-1 and 1.48 for ECA109 under hypoxia. The SERs were 1.25 for TE-1 and 1.32 for ECA109 under normoxia. The in vivo data demonstrated that the combination of CβC and irradiation could inhibit tumor growth to the greatest extent compared with either monotherapy alone. The enhancement factor was 2.45. Conclusion: This study demonstrated that CβC could enhance radiosensitivity of EC cells under hypoxic and normoxic condition. Thus, CβC can be used as an effective radiosensitizer for EC.
- 25 May 2023
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 41 (11) , 1275-1289
Open AccessCurcumol β-cyclodextrin inclusion complex enhances radiosensitivity of esophageal cancer under hypoxic and normoxic condition
Purpose: Radiotherapy is an indispensable treatment for esophageal cancer (EC), but radioresistance is not uncommon. Curcumol, as an active extract from traditional Chinese medicines, has been reported to have antitumor activity in various types of human tumor cells. However, its reversal of radioresistance has been rarely reported. Materials and methods: In the present study, curcumol was prepared as an inclusion complex with β-cyclodextrin. EC cell lines were treated with radiation and curcumol β-cyclodextrin inclusion complex (CβC), and the effect of radiosensitization of CβC was investigated in vitro and in vivo. The in vitro experiments included cell proliferation assay, clonogenic survival assay, apoptosis assay, cell cycle assay, and western blot assay. Results: The in vitro data revealed that CβC and irradiation synergistically inhibited the proliferation, reduced the colony formation, promoted the apoptosis, increased the G2/M phase, inhibited DNA damage repair, and reversed the hypoxia-mediated radioresistance of EC cells to a greater extent than did CβC alone or irradiation alone. The sensitization enhancement ratios (SERs) were 1.39 for TE-1 and 1.48 for ECA109 under hypoxia. The SERs were 1.25 for TE-1 and 1.32 for ECA109 under normoxia. The in vivo data demonstrated that the combination of CβC and irradiation could inhibit tumor growth to the greatest extent compared with either monotherapy alone. The enhancement factor was 2.45. Conclusion: This study demonstrated that CβC could enhance radiosensitivity of EC cells under hypoxic and normoxic condition. Thus, CβC can be used as an effective radiosensitizer for EC.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 3711-3725
Expression levels of chemokine (C-X-C motif) ligands CXCL1 and CXCL3 as prognostic biomarkers in rectal adenocarcinoma: evidence from Gene Expression Omnibus (GEO) analyses
Rectal cancer is a life‑threatening disease worldwide. Chemotherapy resistance is common in rectal adenocarcinoma patients and has unfavorable survival outcomes; however, its related molecular mechanisms remain unknown. To identify genes related to the initiation and progression of rectal adenocarcinoma, three datasets were obtained from the Gene Expression Omnibus database. In total, differentially expressed genes were analyzed from 294 tumor and 277 para-carcinoma samples from patients with rectal cancer. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functions were investigated. Cytoscape software and MicroRNA Enrichment Turned Network were applied to construct a protein-protein interaction network of the dependent hub genes and related microRNAs. The Oncomine database was used to identify hub genes. Additionally, Gene Expression Profiling Interactive Analysis was applied to determine the RNA expression level. Tumor immune infiltration was assessed using the Tumor Immune Estimation Resource database. The expression profiles of hub genes between stages, and their prognostic value, were also evaluated. During this study, data from The Cancer Genome Atlas were utilized. In rectal adenocarcinoma, four hub genes including CXCL1, CXCL2, CXCL3, and GNG4 were highly expressed at the gene and RNA levels. The expression of CXCL1, CXCL2, and CXCL3 was regulated by has-miR-1-3p and had a strong positive correlation with macrophage and neutrophil. CXCL2 and CXCL3 were differentially expressed at different tumor stages. High expression levels of CXCL1 and CXCL3 predicted poor survival. In conclusion, the CXCL1 and CXCL3 genes may have potential for prognosis and molecular targeted therapy of rectal adenocarcinoma. Graphical abstract
- 1 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 3711-3725
Open AccessExpression levels of chemokine (C-X-C motif) ligands CXCL1 and CXCL3 as prognostic biomarkers in rectal adenocarcinoma: evidence from Gene Expression Omnibus (GEO) analyses
Rectal cancer is a life‑threatening disease worldwide. Chemotherapy resistance is common in rectal adenocarcinoma patients and has unfavorable survival outcomes; however, its related molecular mechanisms remain unknown. To identify genes related to the initiation and progression of rectal adenocarcinoma, three datasets were obtained from the Gene Expression Omnibus database. In total, differentially expressed genes were analyzed from 294 tumor and 277 para-carcinoma samples from patients with rectal cancer. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functions were investigated. Cytoscape software and MicroRNA Enrichment Turned Network were applied to construct a protein-protein interaction network of the dependent hub genes and related microRNAs. The Oncomine database was used to identify hub genes. Additionally, Gene Expression Profiling Interactive Analysis was applied to determine the RNA expression level. Tumor immune infiltration was assessed using the Tumor Immune Estimation Resource database. The expression profiles of hub genes between stages, and their prognostic value, were also evaluated. During this study, data from The Cancer Genome Atlas were utilized. In rectal adenocarcinoma, four hub genes including CXCL1, CXCL2, CXCL3, and GNG4 were highly expressed at the gene and RNA levels. The expression of CXCL1, CXCL2, and CXCL3 was regulated by has-miR-1-3p and had a strong positive correlation with macrophage and neutrophil. CXCL2 and CXCL3 were differentially expressed at different tumor stages. High expression levels of CXCL1 and CXCL3 predicted poor survival. In conclusion, the CXCL1 and CXCL3 genes may have potential for prognosis and molecular targeted therapy of rectal adenocarcinoma. Graphical abstract
- Open Access
- 1 August 2017
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 90 (1077) , 20170328
Phase II study of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophagealcancer patients
Objective: A Phase II study was designed to test the safety and efficacy of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophageal cancer patients. Methods: All eligible patients were treated with concurrent chemoradiotherapy. The method of delineating target volume is as follows: Planning gross target volume (PGTV) was defined as the primary gross tumour volume (GTV-t) plus a 3 cm margin longitudinally and a 0.5 cm margin circumferentially, and positive lymph nodes(GTV-n) plus a 0.5 cm margin in all directions. Clinical target volume (CTV) was defined as PGTV plus a 0.5 cm margin in all directions and elective nodal region. Planning target volume (PTV) was defined as CTV plus a 0.5 cm margin in all directions. The dose of PGTV is 54–60 Gy in 27–30 fractions(2Gy per fraction). The dose of PTV is 48.6–54 Gy in 27–30 fractions(1.8Gy per fraction). The regimen consists of paclitaxel135 mgm− 2 on 1 day and DDP 25 mgm− 2 on 3 days per 3 weeks. The patients received 2 cycles of chemotherapy during radiotherapy and 2–4 cycles of chemotherapy after radiotherapy. Results: 34 patients were enrolled in this study. The median follow-up time was 20.9 months (range: 3.7–28.4 months) for all patients. The 1- and 2-year survival rates for all patients were 70.5 and 44.1%, respectively. Clinical complete response was observed in 21 patients(61.8%), cPR was observed in 9 patients(26.5%) and cSD was observed in 4 patients(11.7%). Conclusion: This modified method with concurrent chemotherapy could achieve better locoregional control rate. The 1- and 2-year survival rates of this method were close to the survival rates of the current methods widely adopted. Advances in knowledge: The modified target volumes delineation method can enhance locoregional control rate of concurrent chemoradiotherapy.
- 1 August 2017
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 90 (1077) , 20170328
Open AccessPhase II study of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophagealcancer patients
Objective: A Phase II study was designed to test the safety and efficacy of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophageal cancer patients. Methods: All eligible patients were treated with concurrent chemoradiotherapy. The method of delineating target volume is as follows: Planning gross target volume (PGTV) was defined as the primary gross tumour volume (GTV-t) plus a 3 cm margin longitudinally and a 0.5 cm margin circumferentially, and positive lymph nodes(GTV-n) plus a 0.5 cm margin in all directions. Clinical target volume (CTV) was defined as PGTV plus a 0.5 cm margin in all directions and elective nodal region. Planning target volume (PTV) was defined as CTV plus a 0.5 cm margin in all directions. The dose of PGTV is 54–60 Gy in 27–30 fractions(2Gy per fraction). The dose of PTV is 48.6–54 Gy in 27–30 fractions(1.8Gy per fraction). The regimen consists of paclitaxel135 mgm− 2 on 1 day and DDP 25 mgm− 2 on 3 days per 3 weeks. The patients received 2 cycles of chemotherapy during radiotherapy and 2–4 cycles of chemotherapy after radiotherapy. Results: 34 patients were enrolled in this study. The median follow-up time was 20.9 months (range: 3.7–28.4 months) for all patients. The 1- and 2-year survival rates for all patients were 70.5 and 44.1%, respectively. Clinical complete response was observed in 21 patients(61.8%), cPR was observed in 9 patients(26.5%) and cSD was observed in 4 patients(11.7%). Conclusion: This modified method with concurrent chemotherapy could achieve better locoregional control rate. The 1- and 2-year survival rates of this method were close to the survival rates of the current methods widely adopted. Advances in knowledge: The modified target volumes delineation method can enhance locoregional control rate of concurrent chemoradiotherapy.